AGENUS INC. Files 8-K for Regulation FD and Financial Exhibits
Ticker: AGEN · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1098972
Sentiment: neutral
Topics: Regulation FD, Corporate Filing, Financial Disclosure
TL;DR
**AGENUS INC. just filed a boilerplate 8-K, signaling upcoming disclosures under Regulation FD and new financial exhibits.**
AI Summary
AGENUS INC. filed an 8-K on February 15, 2024, to report an event under Regulation FD Disclosure and to file Financial Statements and Exhibits. This procedural filing indicates that the company has made or will make certain information public, likely related to its operations or financial condition, as required by SEC regulations.
Why It Matters
This 8-K signals that AGENUS INC. has disclosed new material information, which could impact investor perception and stock price once the full details of the Regulation FD disclosure and financial exhibits are known.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing announcing disclosures, not the disclosure itself, so the immediate risk is low until the content is revealed.
Key Players & Entities
- AGENUS INC. (company) — Registrant and Filer
FAQ
What is the purpose of this 8-K filing by AGENUS INC.?
AGENUS INC. filed this 8-K to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the Item Information sections.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported in this 8-K is February 15, 2024.
What is the SEC file number for AGENUS INC.?
The SEC file number for AGENUS INC. is 000-29089.
Where is AGENUS INC.'s principal executive office located?
AGENUS INC.'s principal executive office is located at 3 Forbes Road, Lexington, Massachusetts, 02421.
What was AGENUS INC.'s former company name?
AGENUS INC.'s former company name was ANTIGENICS INC /DE/, with the name change occurring on November 15, 1999.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-02-15 08:00:11
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- agen-20240215.htm (8-K) — 35KB
- agen-ex99_1.htm (EX-99.1) — 24KB
- img250783414_0.jpg (GRAPHIC) — 39KB
- img250783414_1.jpg (GRAPHIC) — 4KB
- 0000950170-24-015604.txt ( ) — 230KB
- agen-20240215.xsd (EX-101.SCH) — 23KB
- agen-20240215_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 15, 2024, Agenus Inc. issued a letter to its stockholders regarding a proposed reverse stock split at a ratio of 1:20. A copy of the letter to stockholders is attached here as Exhibit 99.1, and is incorporated herein by reference. Pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"), the information in this Item 7.01 disclosure, including Exhibit 99.1, and the information set forth therein, is deemed to have been furnished to, and shall not be deemed to be "filed" with, the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Letter to Stockholders, dated February 15, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 15, 2024 By: /s/ Garo H. Armen Garo H. Armen, Chairman and CEO